Three treatment schemes with colloidal bismuth subcitrate (Q-ULCER) in peptic ulcer with Helicobacter pylori

Archives of Medical Research

Volumn 30, Issue 1, 1999, Pages 55-59

  Suárez, Marcia Samada ^a   Cansino, Juan González ^a   Ilizalde, Cira Velasco ^a   Sabatier, Carlos Alfonso ^a   Hernández, Juan Castillo ^b  

^a Ctro de Invest M Q   (Cuba)

^b Ctro de Quim Farmaceut   (Cuba)

Author keywords

Eradication; Healing; Helicobacter pylori

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; EOSIN; HEMATOXYLIN; METRONIDAZOLE; TETRACYCLINE; UREASE;

ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUODENOSCOPY; ERADICATION THERAPY; FEMALE; GASTRODUODENAL ULCER; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; HUMAN TISSUE; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; PEPTIC ULCER; RANDOMIZED CONTROLLED TRIAL; RASH; STATISTICAL ANALYSIS; STOMACH ANTRUM; STOMACH BIOPSY; STOMATITIS;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; COLLOIDS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; DUODENAL ULCER; DUODENOSCOPY; FEMALE; GASTRITIS; GASTROSCOPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; ORGANOMETALLIC COMPOUNDS; PEPTIC ULCER; STOMACH ULCER; TETRACYCLINE; TREATMENT OUTCOME;

EID: 17044455809     PISSN: 01880128     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0188-0128(98)00009-8     Document Type: Article

References (32)

1. Bell G.P., Powell K.V. Eradication of Helicobacter pylori and its effect in peptic ulcer disease. Scand J Gastroenterol. 196(Suppl.):1993;7.
2. Bayerdörffer E., Mannes G.A., Sommer A. Role of Helicobacter pylori in the pathogenesis of gastritis, peptic ulcer and gastric cancer. Scand J Gastroenterol. 196(Suppl.):1993;19.
3. Bockus Gastroenterology. EEUU. 5:1995;W.B. Saunders, Philadelphia.
4. Tytgat G.N.J., Rauws E.A.J. Campylobacter pylori and its role in peptic ulcer disease. Gastroenterol Clin North Am. 19:1990;96.
5. Boixeda D. Tratamiento de la infección del Helicobacter pylori en adultos. Enfermedades Infecciosas y Microbiología Clínica. 12(1):1994;23.
6. Maef G.O. Modern therapies for Helicobacter pylori infection. AGL. 26:1996;119.
7. Ward M., Halliday C., Cowen A. A comparison of colloidal bismuth subcitrate tablets and ranitidine in the treatment of chronic duodenal ulcer. Digestion. 34:1986;173.
8. Axon ATR. Helicobacter pylori therapy: Effect on peptic ulcer disease. In: Working Ponty Report to the World Congress of Gastroenterology, Sidney. 1990. Helicobacter pylori: causal agent in peptic ulcer disease? J Gastroenterol Hepatol 1994;6:7.
9. Samada M., Palomino A., Müller M.E., Castillo J.A. Empleo del subcitrato de bismuto coloidal (Q-ULCER) en el tratamiento de la úlcera péptica gastroduodenal con Helicobacter pylori. Revista CENIC Ciencias Biológicas. 27(1-2-3):1996;54.
10. Chiva N., Rao B.V., Rademaker J.W. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol. 87:1992;1716.
11. Thijs J.C., Van Zwett A.A., Oey H.B. Efficacy and side effects of a triple drug regimen for the eradication of Helicobacter pylori. Scand J Gastroenterol. 28:1993;934.
12. Gorbach S.L. Bismuth therapy in gastrointestinal disease. Gastroenterology. 99:1990;863.
13. Alcalde M., Sánchez P., Lancho A., Rodríguez S.J., Pajares J.M. Subcitrato de bismuto coloidal (SBC). algunas consideraciones farmacocinéticas y de aplicación clínica Rev Esp Enf Digest. 86(5):1994;823.
14. Malfertheiner P. Compliance, adverse events and antibiotic resistence in Helicobacter pylori treatment. Scand J Gastroenterol. 196:1993;34.
15. Cutler A.F., Schubert T.T. Patient factors. effective Helicobacter pylori eradication with triple therapy Am J Gastroenterol. 88:1993;505.
16. Romero J, Hano O, Jiménez G. Eficacia del Q-ULCER y la triple terapia en pacientes con Hp y úlcera péptica gastroduodenal. Tesis de Grado de Especialista en Gastroenterología. Instituto de Gastroenterología. Ciudad de La Habana, Cuba, 1997.
17. Tefera G.M.D., Berstad A.M.D., Bang C.J., Nysaeter G., Hatlebakk J.G., Olafsons S., Nesje L.B. Bismuth-based combination therapy for Helicobacter pylori associated peptic ulcer disease (metronidazole for eradication, ranitidine for pain). Am J Gastroenterol. 91(5):1993;936.
18. Sainz Sáenz-Torre S. Diagnóstico clínico de la infección por Helicobacter pylori en adultos. Enferm Infecc Microbiol Clin. 12(1):1994;14.
19. Mannes GA, Bayerdörffer E, Hũchter W. Relapse Rate of Hp Positive Duodenal Ulcer Following Antibacterial Therapy. The World Congress of Gastroenterology, Sidney, Australia 1990:995 (abstract).
20. Kokozides G, Ketes C, Nikolaides N. Peptic Ulcer Healing with Colloidal Bismuth Subcitrate and Sucralfate in Relation to Campylobacter Pylori. The World Congress of Gastroenterology, Sidney, Australia 1990:330 (abstract).
21. Quintero M., Mederos I., Buesa F., González-Castro R., Haedo W. Ulcera gastroduodenal y Helicobacter pylori. Comportamiento bajo diferentes esquemas de tratamiento. G-E-N. abril-jun. 49(2):1995;116.
22. Coughlan G., Gilligan D., Humphries H. Efficacy of different dosage regimen in duodenal ulcer healing and Campylobacter pylori eradication. Gut. 28(A):1987;1409.
23. Lambert J.R., Borromeo M., Eades E.R. Efficacy of different dosage regimens of bismuth in eradicating Campylobacter pylori. Gastroenterology. 94:1988;248.
24. Rauws E.A.J. Therapeutic attempts at eradication of Campylobacter pylori. Eur J Gastroenterol Hepatol. 1:1989;34.
25. Borody T., Cole P. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust. 151:1989;431.
26. Thijs J.C., Van Zwet A.A., Moolenaar W., Wolfhagen H.M., Ten Bokkel J. Triple therapy vs amoxicillin plus omeprasole for treatment of Helicobacter pylori infection. a multicenter, prospective, randomized, controlled study of efficacy and side effects J Gastroenterol. 91(1):1996;96.
27. O'Riordan T., Mathai E., Tobin E., McKenna D., Keane C., O'Morain C. Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate. Gut. 31:1990;999.
28. Glupezynski Y., Burette A., de Koster E., Nyst J.F., Deltenre M.et al. Metronidazole resistance in Helicobacter pylori. Lancet. 335:1990;976.
29. Glupezynski Y., Burette A. Drug therapy for Helicobacter pylori infection. problems and pitfalls Am J Gastroenterol. 85:1990;1545.
30. Rautelin H., Seppäläk K., Renkonen O., Vainio V., Kosunen T.V. Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother. 36:1992;163.
31. Gisbert J.P., Boixeda D., de Rafae L., Redondo C., Martin de Argila C., Bermejo F. ¿De qué factores depende el éxito de la triple terapia "clásica" en la erradicación de Helicobacter pylori? Rev Esp Enf Digest. 88(5):1996;317.
32. Midolo P.D., Lambert J.R., Turnidge J.J. Metronidazole resistance. a predictor of failure of Helicobacter pylori eradication by triple therapy J Gastroenterol Hepatol. 11(3):1996;290.